# First Tracks Biotherapeutics to Release Phase 1b Celiac Disease Data on Oct. 12

- URL: https://stocks.freetheai.org/news/first-tracks-biotherapeutics-to-release-phase-1b-celiac-disease-data-on-oct-12-e86f45
- Published: 2026-10-11T20:00:00Z
- Category: company_news; sentiment: neutral; impact: medium
- Symbols: [NASDAQ:TRAX](https://stocks.freetheai.org/symbols/NASDAQ-TRAX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

First Tracks Biotherapeutics, Inc. (TRAX) announced that it will publish top-line data from Cohort 1 of its Phase 1b clinical trial evaluating ANB033 on Oct. 12, 2026. The company plans to host a conference webcast at 8:30 a.m. ET to discuss the initial results from the early-stage study in celiac disease.

The Phase 1b trial employs a gluten-challenge framework designed to measure whether ANB033 can protect against intestinal mucosal damage. Early readout figures are critical for biotechnology companies, as safety and efficacy signals from preliminary cohorts often determine the clinical viability and future direction of experimental therapies.

Investors will monitor the upcoming data presentation for initial indicators of efficacy and tolerability. Broader trial cohorts and potential regulatory feedback will serve as key milestones for the ANB033 development program moving forward. Ahead of the data release, shares of First Tracks Biotherapeutics were trading at $31.85, down 0.50% on the day.

## Key points

- First Tracks Biotherapeutics scheduled the top-line readout for Cohort 1 of its Phase 1b ANB033 trial for Oct. 12, 2026.
- The Phase 1b study uses a gluten-challenge design to evaluate ANB033's ability to prevent mucosal damage in celiac disease.
- Management will host a public webcast to present the initial clinical results at 8:30 a.m. ET.
- Shares of First Tracks Biotherapeutics (TRAX) traded down 0.50% at $31.85 ahead of the announcement.

## Questions and answers

### When will First Tracks Biotherapeutics release its ANB033 trial data?

First Tracks Biotherapeutics will release top-line Phase 1b data for ANB033 on Oct. 12, 2026, at 8:30 a.m. ET.

### What is the Phase 1b ANB033 trial studying?

The trial evaluates ANB033 in celiac disease using a gluten-challenge design to see if it prevents mucosal damage.